Shots:

• The BT designation is based on P-III ADAURA trial which involves assessing Tagrisso (80 mg) vs PBO in 682 patients with Stage IB- II- IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated across 20 centers and 200+ countries including the US- EU- South America- Asia- and the Middle East
• The study resulted in improvement in DFS- reduction in risk of disease recurrence- or death by 79% in the adjuvant treatment of Stage IB-IIIA EGFRm NSCLC patients- also presented at ASCO 2020. Additionally- the trial will continue to assess OS
• Tagrisso (osimertinib) is third-generation- irreversible EGFR-TKI once-daily oral tablets approved 1st-line EGFRm advanced NSCLC and EGFR T790M mutation-positive advanced NSCLC in the US- Japan- China- the EU

Ref: AstraZeneca | Image: AstraZenca